VAXART, INC Net Cash Flow 2010-2025 | VXRT

VAXART, INC net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.

VAXART, INC Net Cash Flow 2010-2025 | VXRT

VAXART, INC net cash flow from 2010 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$72.3B
Zoetis (ZTS)$68.6B
Takeda Pharmaceutical (TAK)$47.6B
Daiichi Sankyo, - (DSNKY)$46.4B
BeOne Medicines - (ONC)$32.7B
Sandoz Group AG (SDZNY)$27.7B
Summit Therapeutics (SMMT)$18.1B
Merck (MKKGY)$16.3B
Shionogi (SGIOY)$14.8B
United Therapeutics (UTHR)$13.9B
Neurocrine Biosciences (NBIX)$13.8B
IPSEN (IPSEY)$11.6B
Orion OYJ (ORINY)$11.2B
Madrigal Pharmaceuticals (MDGL)$9.7B
Eisai (ESAIY)$9.1B
Corcept Therapeutics (CORT)$7.3B
Stevanato Group S.p.A (STVN)$7.1B
Ionis Pharmaceuticals (IONS)$6.8B
Grifols, S.A (GRFS)$6.8B
Ono Pharmaceutical (OPHLF)$5.7B
Hikma Pharmaceuticals Plc (HKMPF)$5.4B
Soleno Therapeutics (SLNO)$3.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
Hypermarcas (HYPMY)$2.8B
Procaps Group, S.A (PROCF)$2.8B
NewAmsterdam Pharma (NAMS)$2.7B
Catalyst Pharmaceuticals (CPRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.2B
Ocular Therapeutix (OCUL)$2.2B